Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Imvax, Inc.

News headline image
Imvax Announces Additional Data from Phase 2b Clinical Trial of IGV-001 in Newly Diagnosed GBM and Provides Update on Planned Clinical Development
From Imvax, Inc.
Via Business Wire
News headline image
Imvax Announces Positive Top-line Data from Phase 2b Clinical Trial of IGV-001 in Newly Diagnosed GBM
From Imvax, Inc.
Via Business Wire
News headline image
Imvax Announces Completion of $29 Million Financing and Confirms Timing for Topline Results of Phase 2b Trial of IGV-001 in Newly Diagnosed Glioblastoma
From Imvax, Inc.
Via Business Wire
News headline image
Imvax to Present Safety Data on Lead Program, IGV-001, at 2024 SNO Annual Meeting
From Imvax, Inc.
Via Business Wire
News headline image
Imvax Announces Completion of Enrollment in Phase 2b Clinical Trial of IGV-001 and Successful Financing
From Imvax, Inc.
Via Business Wire
News headline image
Imvax Presents New Data at 2023 SNO Annual Meeting Supporting its Lead Program, IGV-001, in Newly Diagnosed Glioblastoma
From Imvax, Inc.
Via Business Wire
News headline image
Imvax to Present New Data on Lead Program, IGV-001, at 2023 SNO Annual Meeting
From Imvax, Inc.
Via Business Wire
News headline image
Imvax Provides Corporate Update
From Imvax, Inc.
Via Business Wire
News headline image
Imvax Announces Publication in Journal for ImmunoTherapy of Cancer Showing IGV-001 Can Induce Clinically Relevant Anti-Cancer Immune Responses in Glioblastoma via Immunogenic Cell Death
From Imvax, Inc.
Via Business Wire
News headline image
Imvax Presents New Data at AACR 2023 Supporting the Mechanism of Action of its Lead Program, IGV-001, for Glioblastoma
From Imvax, Inc.
Via Business Wire
News headline image
Imvax Announces First Patient Dosed in Phase 2b Trial of IGV-001 for Glioblastoma
From Imvax, Inc.
Via Business Wire
News headline image
Imvax Presents Preclinical Data at SITC 2022 Supporting Mechanism of Action and Anti-tumor Activity of its Immunotherapy Platform Across Multiple Tumor Types
From Imvax, Inc.
Via Business Wire
News headline image
Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 SITC Meeting
From Imvax, Inc.
Via Business Wire
News headline image
Imvax Presents New Data on Personalized Whole-Tumor Derived Immunotherapeutic Platform at 2022 International Cancer Immunotherapy Conference
From Imvax, Inc.
Via Business Wire
News headline image
Imvax to Present at Two Investor Conferences in May
From Imvax, Inc.
Via Business Wire
News headline image
Imvax Presents New Data on Tumor-Derived Immunotherapies in Glioblastoma, Other Solid Tumors at AACR Annual Meeting 2022
From Imvax, Inc.
Via Business Wire
News headline image
Imvax Presents Data Showing Mechanisms for Broad Immune Activation by IGV-001
From Imvax, Inc.
Via Business Wire
News headline image
Imvax to Present Preclinical Data on IGV-001 Mechanism of Action at SITC Annual Meeting
From Imvax, Inc.
Via Business Wire
News headline image
Imvax Appoints John M. Limongelli as Chief Legal Officer
From Imvax, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.